New Retina Radio
New Retina Radio

02.11.22

Exploring the clinical development program for an innovative, continuous delivery treatment for nAMD

Recently, the first refillable, intraocular device that enables continuous delivery of therapy was FDA approved for nAMD. John Kitchens, MD sits down with one of the investigators, Dante Pieramici, MD, to learn more about his experiences with the clinical development program and this innovative drug delivery system. This special episode of New Retina Radio is supported by Genentech USA, Inc., which is responsible for its content.

View full description +

MORE EPISODES

07.08.26

Barriers to Care, Patient Education, and Treatment Decisions in Geographic Atrophy

Geeta Lalwani, MD; Murtaza Adam, MD; and Carl Danzig, MD

07.08.26

Evolving Practice Patterns and Dosing Strategies in Geographic Atrophy

Geeta Lalwani, MD; Murtaza Adam, MD; and Carl Danzig, MD

07.08.26

Biomarkers, Imaging, and Early Treatment Decisions in Geographic Atrophy

Geeta Lalwani, MD; Murtaza Adam, MD; and Carl Danzig, MD

07.01.26

The Fellow Eye: Episode 5

Justin C. Muste, MD; David Fell, MD; Omesh P. Gupta, MD; and Shane Griffin, MD, MCR

06.26.26

Retinal Perfusion, Sensitivity, and Function in DR

Barton Blackorby, MD; Katherine Talcott, MD; and Hong-Uyen Hua, MD

06.22.26

Spotlight on UNITY® VCS: Experience Extraordinary

Kourous Rezaei, MD; with Lejla Vajzovic, MD, FASRS and Aleksandra Rachitskaya, MD, FASRS

06.18.26

ARVO '26: TKIs for Wet AMD and How We Got to the AI Era of Research

Akshay Thomas, MD; Aaron Lee, MD, MSCI; and Cecelia Lee, MD, MS

06.15.26

Spotlight on UNITY® VCS Dynamic Stiffener 27+

Christina Weng, MD, MBA, FASRS; Mrinali Gupta, MD, FASRS; and Omesh Gupta, MD, MBA

Show More